iTeos to Report Third Quarter 2021 Financial Results on November 10, 2021
CAMBRIDGE, Mass. and GOSSELIES, Belgium, Nov. 03, 2021 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, today announced that it will host a conference call and live webcast at 4:30 p.m. ET on Wednesday, November 10, 2021 to report its third quarter 2021 financial results and provide a corporate update.
To access the live conference call, please dial 833-927-1758 (domestic) or 929-526-1599 (international) and refer to conference access code 861337. A live audio webcast of the event will also be accessible from the News and Events page of the Company’s website at https://investors.iteostherapeutics.com/news-and-events/events. The archived webcast will be available approximately two hours after the completion of the event and for one week following the call.
To pre-register for the event, please use the following link to receive access details via email:
https://www.incommglobalevents.com/registration/q4inc/9144/iteos-therapeutics-q3-2021-earnings-conference-call/.
About iTeos Therapeutics, Inc.
iTeos Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients. iTeos Therapeutics leverages its deep understanding of cancer immunology and immunosuppressive pathways to design novel product candidates with the potential to fully restore the immune response against cancer. The Company’s innovative pipeline includes two clinical-stage programs targeting novel, validated immuno-oncology pathways designed with optimized pharmacologic properties for improved clinical outcomes. The first antibody product candidate, EOS-448, is a high affinity, potent, anti-TIGIT antibody with a functional Fc domain, designed to enhance the anti-tumor response through a multifaceted immune modulatory mechanism, currently progressing in multiple indications in collaboration with GSK. The Company is also advancing inupadenant, a next-generation adenosine A2A receptor antagonist tailored to overcome cancer immunosuppression into proof-of concept trials in several indications following encouraging single-agent activity in Phase 1. iTeos Therapeutics is headquartered in Cambridge, MA with a research center in Gosselies, Belgium.
For further information, please contact:
Investor Contact:
Ryan Baker
iTeos Therapeutics, Inc.
Ryan.Baker@iteostherapeutics.com
Media Contact:
media@iteostherapeutics.com
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Company announcement no 8 Idavang 2024 Annual General Meeting 26-04-202426.4.2024 10:45:00 CEST | Press release
Annual General Meeting 26th April 2023 Idavang A/S CVR 30 95 61 43 The agenda of the annual meeting of shareholders Election of chairman for the annual meeting of shareholdersPresentation of the annual report along with any director’s report and adoption of the annual reportResolution on the distribution of the profit recorded in the adopted annual reportElection of directors 5 existing members of the boards nominated (Niels Hermansen, Ole Bjerremand Hansen, Carsten Lund Thomsen, Jytte Rosenmaj and Claus Baltsersen) as members of the boardDecision on fee to directorsAppointment of auditor, if requiredAOB The decision of annual meeting of shareholders (all unanimous) In favor of electing Mr. Michael Henriksen the chairman for the annual meetings of shareholders of Idavang A/S. In favor of the decision to adopt annual report of Idavang A/S. In favor of the decision, all decisions that retain the full net profit for the year ended December 31, 2023 in Retained Earnings attributed to Idava
Company announcement no 7/2024 Annual account 202326.4.2024 10:45:00 CEST | Press release
Annual account 2023 Please find enclosed the full annual account for Idavang A/S in pdf No changes in financial figures compared to Q4 report published end February If you wish to download the annual account file : IDAVANG-2023-12-31-en Please use the following link bit.ly/Idavang2023 Attachments Company announcement no 7 2024 Zip fileIdavang Annual Report 2023
Aktietilbagekøbsprogram26.4.2024 10:18:43 CEST | pressemeddelelse
Nørresundby, 26. april 2024 Meddelelse nr. 23/2024 Bestyrelsen i RTX har, jf. selskabsmeddelelse nr. 20/2023 af 30. november 2023, besluttet at iværksætte et aktietilbagekøbsprogram i overensstemmelse med bestemmelserne i artikel 5 i Europa-Parlamentets og Rådets forordning (EU) nr. 596/2014 af 16. april 2014 (MAR) og Kommissionens delegerede forordning (EU) 2016/1052, også kaldet "Safe Harbor"-forordningen. Under programmet vil RTX tilbagekøbe aktier for et beløb på op til DKK 20 mio. i perioden fra 1. december 2023 til 30. september 2024. Følgende transaktioner er foretaget under programmet i perioden nedenfor: Antal aktierGennemsnitlig købsprisTransaktionsværdi i DKKRTX-aktier før programmets start258.52800Akkumuleret andel i programmet, seneste udmelding 154.620 13.070.910 19. april 202480094,9075.92022. april 202480095,7076.56023. april 202480095,0076.00024. april 202480995,1877.00125. april 20249009686.319Akkumuleret under programmet 158.729 84,82 13.462.709 RTX i alt aktier8.467
Share repurchase programme26.4.2024 10:18:43 CEST | Press release
Nørresundby, 26 April 2024 Announcement no. 23/2024 The Board of Directors of RTX has, cf. company announcement no. 20/2023 dated 30 November 2023, resolved to initiate a share buy-back programme in accordance with the provisions of Article 5 Regulation (EU) No. 596/2014 of the European Parliament and of the Council of 16 April 2014 (MAR) and the Commission’s delegated Regulation (EU) 2016/1052, also referred to as the "Safe Harbor" regulation. Under the programme RTX will buy back shares for an amount up to DKK 20 million in the period from 1 December 2023 to 30 September 2024. The following transactions have been made under the programme in the period below: Number of SharesAverage Purchase PriceTransaction value in DKKRTX shares prior to initiation of the programme258,528Accumulated share in the programme, latest announcement 154,620 13,070,910 19 April 202480094.9075,92022 April 202480095.7076,56023 April 202480095.0076,00024 April 202480995.1877,00125 April 202490095.9186,319Accum
Composition of the Nomination Committee of Orion Corporation26.4.2024 10:15:00 CEST | Press release
ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE 26 APRIL 2024 at 11.15 EEST Composition of the Nomination Committee of Orion Corporation The Board of Directors of Orion Corporation has appointed the following persons to the Nomination Committee of the company: Annika EkmanPetteri KarttunenMinna MaasiltaVeli-Matti MattilaHilpi RautelinSeppo Salonen Hilpi Rautelin was appointed as Chair of the Committee. The Committee prepares and presents a recommendation to the Board of Directors for the proposal to the Annual General Meeting concerning the composition of the Board. The essentials of the charter of the Nomination Committee and a description of the appointment process of its members are provided at https://www.orion.fi/en/investors/corporate-governance/board-of-directors/nomination-committee/charter-of-the-nomination-committee/ , a page in the Corporate Governance section of the Orion Group website. Orion Corporation Liisa Hu